Singlet oxygen tends to rip apart tumor cells in a manner that exposes many
new tumor antigens to immune cells called dendritic cells, which, like police executing a dragnet, grab the antigens and present them to T cells for closer inspection.
Not exact matches
One of the 43 began producing a
new protein, which the researchers took to be an antibody to the
tumor antigen.
A relatively
new biomarker called prostate - specific membrane
antigen (PSMA) is the bullseye for three
new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of
tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Dr. Gnjatic's research focuses on human
antigen - specific immune responses to
tumor antigens, in an attempt to define
new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.
Researchers now think that irradiation sometimes kills
tumor cells in a manner that exposes
new antigens to T cells, priming them to target other
tumor cells that carry them as well, says Wenbin Lin, a chemist at the University of Chicago in Illinois, and one of the authors of the current study.
Baltimore, Md. (Embargoed until 12:30 pm EDT on Monday, June 8)-- A relatively
new biomarker called prostate - specific membrane
antigen (PSMA) is the bullseye for three
new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of
tumor types, according to research unveiled at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Thierry Boon and colleagues show that immunogenic mutagenized
tumor variants (tum) express
new antigens recognized by cytotoxic T lymphocytes (CTLs).
The team is also working to discover
new antigens that the ATRX - deficient brain
tumor cells may have.
«We are excited to be a part of this important
new initiative to develop novel treatment options for patients,» said Ovid Trifan, M.D., Ph.D., chief medical officer of Apexigen, Inc. «APX005M is a potential best - in - class CD40 agonist that works by activating the immune system's
antigen - presenting cells in the
tumor microenvironment.